Roche abandons anti-myostatin approach to Duchenne MD — one more nail in the class' coffin
Roche has joined a line of drugmakers retreating from one class of experimental Duchenne muscular dystrophy drugs, dealing another blow to the theory that inhibiting myostatin can slow the muscle-wasting disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.